| Autor: |
Masatsugu Nozoe, MD, PhD, Toshihiro Honda, MD, PhD, Mitsuko Honda, MD, PhD, Kazuya Ichikado, MD, PhD, Moritaka Suga, MD, PhD, Koichi Nakao, MD, PhD |
| Jazyk: |
angličtina |
| Rok vydání: |
2013 |
| Předmět: |
|
| Zdroj: |
Journal of Arrhythmia, Vol 29, Iss 1, Pp 5-8 (2013) |
| Druh dokumentu: |
article |
| ISSN: |
1880-4276 |
| DOI: |
10.1016/j.joa.2012.04.005 |
| Popis: |
Background: Amiodarone is a useful antiarrhythmic drug, especially in patients with serious heart diseases, but amiodarone-induced interstitial pneumonia (AMD-IP) is sometimes lethal. Methods and results: We retrospectively analyzed the clinical characteristics of 280 patients who were treated with daily oral amiodarone. Among the patients, 29 (10.2%) developed AMD-IP during the follow-up period of 66.0±38.2 months. The average dose of amiodarone in the AMD-IP group (173±10 mg) was significantly higher than that in the non-AMD-IP group (150±3 mg). The prevalence of smoking history (AMD-IP group: 70.0%; non-AMD-IP group: 42.2%; P5 years, 10.2% of patients receiving low-dose amiodarone therapy developed AMD-IP. Higher maintenance doses, smoking history, and preexisting lung disease were related to the development of AMD-IP. The AMD-IP patients with COPD had a poor prognosis. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text